The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2016 | Results of KEYNOTE-023 and pembrolizumab plus pomalidomide trials for multiple myeloma
Jesús San Miguel, MD, PhD, from the University of Navarra, Navarra, Spain gives an overview of his talk on ‘Immunotherapy checkpoint inhibitor trials’ presented at the Myeloma 2016 meeting in Boston, MA. First, Prof San Miguel discusses the lenalidomide and pembrolizumab KEYNOTE-023 trial (NCT02036502). The treatment was well tolerated and the response rate was 76% for the overall population and 50% for the double refractory population. Then, he discusses the trial of pembrolizumab plus pomalidomide (NCT02289222); the response rate was 60% for the overall population and 50% for the double refractory population.
Recorded at the Myeloma 2016 meeting held in Boston, MA.
